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Background: The diagnosis of diabetes mellitus (DM) is based on either fasting plasma glucose levels or an oral
glucose tolerance test (OGTT). Recently, an HbA1c value of ≥ 48 mmol/mol (6.5%) has been included as an
additional test to diagnose DM. The purpose of this study was to validate HbA1c versus OGTT as a method to
diagnose DM in vascular surgery patients.
Methods: The study population consisted of 345 patients admitted consecutively due to peripheral arterial disease.
Sixty-seven patients were previously diagnosed with DM. Glucose levels of OGTT and HbA1c values were analyzed
in 275 patients. The OGTT results were categorized into three groups according to the World Health Organization
1999 criteria: 1) DM defined as fasting plasma glucose (FPG) ≥ 7.0 mmol/L and/or two-hour value (2-h-value) ≥
11.1 mmol/L; 2) intermediate hyperglycaemia, which consists of IGT (FPG < 7.0 mmol/L and a 2-h-value between
7.8 mmol/L and 11.1 mmol/L), and IFG (fasting glucose value between 6.1 mmol/L and 7.0 mmol/L with a normal
2-h-value); and 3) normal glucose metabolism defined as FPG < 6.1 mmol/L and a 2-h-value < 7.8 mmol/L.
Results: Of the 275 patients on whom OGTT was performed, 33 were diagnosed with DM, 90 with intermediate
hyperglycaemia and 152 had normal glucose metabolism. An HbA1c value of ≥ 48 mmol/mol (6.5%) detected DM
with a 45.5% sensitivity and a 90% specificity compared with the OGTT results. Combining the measurements of
the HbA1c value with the fasting plasma glucose level (≥7.0 mmol/L) increased the sensitivity to 64%. The total
prevalence of DM and intermediate hyperglycaemia was 85% based on HbA1c values and 45% based on the OGTT.
Conclusions: Compared with the OGTT the HbA1c cut-off value of ≥ 48 mmol/mol (6.5%) had a 45.5% sensitivity to
diagnose DM in patients with peripheral arterial disease. OGTT and HbA1c categorized different individuals with DM
and intermediate hyperglycaemia. The total prevalence of pathologic glucose metabolism was substantially higher
based on HbA1c values than based on OGTT. The high prevalence of DM and intermediate hyperglycaemia when
using HbA1c in this study may reflect a high chronic glycaemic burden in patients with peripheral arterial disease.
Further studies on vascular surgery patients are needed to identify which method, OGTT or HbA1c, is the better in
predicting DM and future clinical development of vascular disease.
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Figure 1 Flow chart. The selection of patients admitted
consecutively to the vascular surgery unit at Haukeland University
Hospital, Norway, for elective surgery between October 2006 and
September 2007.
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The diagnosis of diabetes mellitus (DM) has, until re-
cently, been based on blood glucose levels, i.e. either
fasting plasma glucose (FPG) ≥7.0 mmol/l or an oral glu-
cose tolerance test (OGTT) result of ≥11.1 mmol/l [1].
The HbA1c value reflects the average blood glucose
over a 2-3 month period and has traditionally been used
to evaluate the treatment of established DM. It has been
described as a predictor for DM and of micro- and
macrovascular disease [2-6]. Studies have shown a lin-
ear increase in retinopathy prevalence for HbA1c at
48 mmol/mol (6.5%) and above [7,8]. However, an in-
crease in retinopathy is also seen in the intermediate
hyperglycaemia (prediabetes) range of HbA1c and the
overall risk assessment for DM is seen as a continuum
from low risk to established DM [8].
The International Expert Committee of Diabetes,
American Diabetes Association and the World Health
Organization (WHO) have included HbA1c value ≥
48 mmol/mol (6.5%) as an additional method for diag-
nosing DM [8-10].
Two intermediate HbA1c ranges of 39-46 mmol/mol
(5.7-6.4%) (American Diabetes Association) and of 42-46
mmol/mol (6.0 – 6.4%) (the International Expert Com-
mittee) have been suggested to be used to identify indi-
viduals at high risk for developing DM [8,9]. The WHO
has not yet made a statement on the HbA1c diagnostic
range of intermediate hyperglycaemia.
Previous studies have revealed a higher prevalence of
DM in patients with peripheral arterial disease (PAD)
[11-13] compared to general populations [14-16] and
populations at risk of developing DM [17]. In all age
groups the prevalence of DM in Norway is estimated to
be 2.3%, with a prevalence of 3.4% among those aged
≥30 years. This increases with age to approximately 8%
amongst the elderly (70-79 years) [18]. Results from the
Nord-Trøndelag Diabetes Study indicate a prevalence of
IGT in Norway at 0.9% in men and 0.2% in women
using WHO 1980 criteria (IGT: 2-h-value between
8.0 mmol/L and 10.9 mmol/L). The study was based on
a pre selection of patients with an abnormal non-fasting
glucose value (≥ 8.0 mmol/L). The use of an initial
screening test and a threshold value for follow-up at
8.0 mmol/L may have led to an underestimation of the
total IGT prevalence[19]. The prevalence of impaired
fasting glucose (IFG) in Norway is not known. A prior
publication based on this study material revealed a
prevalence of pathologic glucose metabolism of 55% and
a frequency of diabetes of 29% among Norwegian vascu-
lar surgery patients [13].
Most studies that investigated the use of HbA1c values
against OGTT as a diagnostic tool for DM have found
reduced prevalence by HbA1c criteria compared with the
OGTT criteria. The studies also showed discordancebetween OGTT and HbA1c values suggesting that
the two methods define different patient categories
[14-17,20,21]. Patients with PAD are multimorbid and
of high age[13]. It is important to evaluate whether re-
sults from studies on general populations and popula-
tions at risk of developing DM are applicable on this
high-risk population of patients with PAD. No previous
studies that have validated the use of HbA1c values
against OGTT in the diagnosis of DM in vascular sur-
gery patients could be found, hence the purpose of the
present study.
Methods
Patient selection
This study was a prospective cohort study. The study
population consisted of 345 patients admitted consecu-
tively to the vascular surgery unit for elective surgery be-
tween October 2006 and September 2007. Initially 466
patients were asked to participate, however 121 declined.
DM was previously diagnosed in 67 patients (Figure 1).
This left data from 275 patients (273 ethnic Norwegians
and 2 white Europeans) for analyses. Informed written
consent was obtained from all participants. The research
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Medical Research Ethics (REK vest 14109). The vascular
pathologies were peripheral arterial disease including
iliac occlusive disease (IOD), infrainguinal occlusive dis-
ease, abdominal aortic aneurismal disease and carotid
stenosis.
Diagnostic tests
An OGTT was performed on the 275 participating pa-
tients. Fasting glucose and HbA1c values were measured
in all patients. OGTT was performed after a minimum
of 8 hours overnight fasting, by orally administering a
standard dose of 75 g anhydrous glucose dissolved in
water. Plasma glucose levels were measured in a fasting
state prior to administering the anhydrous glucose and
again two hours after its administration. The patients
were not recommended any special diet prior to the
OGTT. In 61 patients (22%) the OGTT was performed
at their respective General Practitioner’s (GP’s) offices
due to logistic reasons. The results from these tests were
also analysed at their GP’s offices in 27 patients (44%), at
Haukeland University Hospital in 17 patients (28%) and
at other regional hospitals in 17 patients (28%). Venous
whole blood, drawn in containers with glycolytic inhibi-
tors (citrate and fluoride) and centrifuged within one
hour from venous sampling to separate plasma, was
used for the OGTT glucose measurements performed at
Haukeland University Hospital. Blood glucose during the
OGTT performed at the GP’s offices was analysed im-
mediately in capillary whole blood. The preanalytical
handling of the bloodsamples for the OGTTs performed
at other regional hospitals is not known.
The OGTT plasma glucose levels were analysed using
the available resources at the different hospital laborator-
ies: Modular P (Roche Diagnostics) (78% of the blood
samples were analysed using Modular P), Vitros 950
(Ortho-Clinical Diagnostics), Architect ci 8200 (Abbott),
Architect c 8000 (Abbott), and Hitachi 911 (Roche
Diagnostics). At the GP’s offices the following resources
were used for analysis: Hemocue 201+ (Photometer),
Hemocue B-glucose promedico and Reflotron +. The
range of the coefficients of variation on the equipment
used for glucose value analyses at the different hospital
laboratories was 1.8% -3.0%. Analytical discrepancies on
the equipment used for analysis at the GP´s offices were
referred to as accepted or not accepted, and were all
within accepted values set by NOKLUS.
External quality assessment of all equipment used for
analysis was performed by NOKLUS. NOKLUS is a
national institution certified by The National Institute
of Technology (NS-EN ISO 9001:2000), and run by
a committee consisting of representatives from The
Norwegian Crown, The Norwegian Medical Association
and The Norwegian Association of Local and RegionalAuthorities. NOKLUS is quality checked by The Euro-
pean Reference Laboratory for Glycohemoglobin in the
Netherlands.
The OGTT results were categorized into three groups
according to the WHO 1999 criteria: 1) DM defined as
fasting plasma glucose (FPG) ≥ 7.0 mmol/l and/or two-
hour value (2-h-value) ≥ 11.1 mmol/l 2) intermediate
hyperglycaemia, which consists of IGT defined as FPG <
7.0 mmol/L and a 2-h-value between 7.8 mmol/L and
11.1 mmol/L, and IFG defined as fasting glucose value
between 6.1 mmol/L and 7.0 mmol/L with a normal 2-h
-value and 3) normal glucose metabolism defined as
FPG < 6.1 mmol/L and a 2-h-value < 7.8 mmol/L.
HbA1c values were measured on all participants through
a single blood sample, mainly at Haukeland University
Hospital (98% of the blood samples were analysed in the la-
boratory at Haukeland University Hospital using Variant II
HPLC system). Four patients were tested at their GP’s of-
fice, and three patients at other regional hospitals. HbA1c
values were then analysed using the following resources:
Variant II HPLC system (BioRad), DCA2000, DCAVantage
(Siemens), Hitachi 912 (Roche Diagnostics), D-10 (BioRad),
Nycocard reader (Axis-Shield) and Architect ci 8200
standardized immunoassay. The range of the coeffi-
cients of variation on the equipment used for HbA1c
level analyses was 0.8%-2.6% at HbA1c values 5.4%-9.8%.
Two bloodsamples were analysed on DCA 2000 with
coefficients of varation of 4.2%-5.2% at HbA1c 5.0%. The
analysing equipment used standardised assay in accord-
ance with DCCT standard.
The HbA1c results were categorized as: DM, intermedi-
ate hyperglycaemia and normoglycaemia. The diagnostic
limit of HbA1c is ≥48 mmol/mol (6.5%) according to
WHO statement 2011. The American Diabetes Association
definition of intermediate hyperglycaemia at 39-46 mmol/
mol (5.7-6.4%) was used since WHO has not yet made a
statement on the HbA1c diagnostic range of intermediate
hyperglycaemia.
Other variables
Information about age (continuous), sex (men/women),
smoking habits (yes/no), affected vascular bed, state of an-
aemia (yes/no) and kidney failure (yes/no) was obtained
from the patients’ medical records. The presence of kidney
failure and anaemia was defined based on estimated glom-
erular filtration rates and serum haemoglobin levels. Esti-
mated GFR values were calculated by The Modification of
Diet in Renal Disease equation. According to international
recommendations all patients treated at the Vascular
Surgery Department were given statins and anti-platelet
medication, unless strong contraindications were present.
Angiotensin Converting Enzyme Inhibitor/Angiotensin re-
ceptor blocker was the preferable choice when treating
hypertension.
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Data were analysed using SAS version 9.2 (SAS Institute,
Inc., Cary, North Carolina) and R version 2.8.1 (The R
Foundation for Statistical Computing, www.r-project.
org) software for Windows. All p values were 2-sided,
and values <0.05 were considered statistically significant.
The data is presented as mean±standard error for
continuous data and as percentage±standard error forTable 1 Baseline characteristics of the study population
Characteristics
All Norm
patients glycae
Total 275
Age, mean years 69.5
range] [35-89] [35
Sex, n (%)
Female 74 (26.9) 51 (3
Male 201 (73.1) 101 (6
Smoking status, n (%)
Non-smoker 42 (15.3) 23 (1
Former/current smoker 221 (80.4) 123 (8
Missing 12 (4.36) 6 (3
Renal function, n (%)
Normal (eGFR > 60) 201 (73.1) 120 (7
Reduced (eGFR < 60) 71 (25.8) 31 (2
Missing 3 (1.09) 1 (0
Anemia female, n (%)
No anemia 61 (82.4) 43 (8
Female Hb < 11.7 g/dL 6 (8.11) 4 (7
Missing 7 (9.46) 4 (7
Anemia male, n (%)
No anemia 163 (81.1) 81 (8
Male Hb < 13.4 g/dL 29 (14.4) 16 (1
Missing 9 (4.48) 3 (2
Medical history of CAD, n (%)
No 231 (84.0) 129 (8
Yes 42 (15.3) 22 (1
Missing 2 (0.73) 1 (0
Affected vascular bed, n (%)
Carotid 43 (15.6) 26 (1
Aortic 59 (21.5) 30 (1
IOD 50 (18.2) 35 (2
Infrainguinal 123 (44.7) 61 (4
Fasting glucose, mean mmol/L (SE) 5.70 (0.05) 5.27 (0
HbA1c, mean% (SE) 6.1 (0.03) 6.0 (0
a Chi-square test for categorical data and Wald-test for continuous data.
b Fisher’s exact test.categorical data. Correlation between pairs of continuous
measures was calculated using the Spearmans correl-
ation coefficient. Associations between categorical vari-
ables were analysed using χ2 test. When the expected
number of observations in one or more categories was ≤ 5,
we used the Fisher’s exact test.
Segmented regression analysis (the segmented package
in R) was used to examine the association between theOGTT
o- Intermediate Diabetes P-
mia hyperglycaemia mellitus valuea
152 90 33
68.0 71.5 71.1 0.01
-87] [48-89] [59-88]
0.02
3.6) 15 (16.7) 8 (24.2)
6.5) 75 (83.3) 25 (75.8)
0.06
5.1) 10 (11.1) 9 (27.3)
0.9) 77 (85.6) 21 (63.6)
.95) 3 (3.33) 3 (9.09)
0.04
9.0) 57 (63.3) 24 (72.7)
0.4) 31 (34.4) 9 (27.3)
.66) 2 (2.22)
4.3) 10 (66.7) 8 (100) 0.52b
.84) 2 (13.3) 0
.84) 3 (13.3) 0
1.2) 62 (82.7) 19 (76.0) 0.81b
5.8) 9 (12.0) 4 (16.0)
.97) 4 (5.33) 2 (8.00)
0.67
4.9) 73 (81.1) 29 (87.9)
4.5) 16 (17.8) 4 (12.1)
.66) 1 (1.11) 0
0.16
7.1) 11 (12.2) 6 (18.2)
9.7) 23 (25.6) 6 (18.2)
3.0) 9 (10.0) 6 (18.2)
0.1) 47 (52.2) 15 (45.5)
.04) 5.90 (0.05) 7.11(0.24) <0.001
.03) 6.1 (0.05) 6.5 (0.13) <0.001
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provides separate regression coefficients for potential
piecewise linear relations. To estimate the breakpoint
between two segmented relations, the method uses in-
formation from the Davies’ test for a non-zero difference
in slope between variables. The HbA1c values in this
population ranged from 5% to 9%. Only five persons had
HbA1c value above 7%. Although the corresponding
glucose levels for the five patients were highly plausible,
potential outliers may have influenced the estimation of
cut-points in segmented regression. Therefore the seg-
mented regression analyses were performed with and
without these five subjects. No difference in estimated
cut-points was found, suggesting that patients with an
HbA1c value above 7% did not compromise the validity
of the present segmented regression.
Receiver operating characteristic (ROC) curves and
the area under the curve (AUC) were used to evaluate
the performance of HbA1c when using the OGTT cri-
teria as the gold standard. AUC was estimated for all
study participants, including the subpopulation where
HbA1c values were measured within one month after the
OGTT, and the subpopulation where HbA1c values were
measured within two months after the OGTT.Results
Baseline characteristics of the study population are shown
in Table 1. According to the OGTTcriteria the prevalence
of DM was 12% and the prevalence of intermediate
hyperglycaemia was 33%.
The prevalence of reduced renal function was 20% in
the normoglycaemic group, 34% in the intermediate
hyperglycaemic group and 27% among the patients diag-
nosed with DM (p = 0.04). No statistically significant
relation between reduced renal function and HbA1c
values was seen (p = 0.46). The majority of the study
population was current or former smokers (80%). There
were no significant differences in OGTT values and
HbA1c values with respect to vessels tested (carotid,
aortic, iliac, infrainguinal) (p = 0.16). Separate analysis of
glycaemic categories according to HbA1c values revealed
no statistically significant differences in age, sex, smok-
ing status, renal function, anaemia, coronary heart dis-
ease or affected vascular bed.
Segmented regression analysis of FPG on HbA1c values
indicated a breakpoint at an HbA1c value of 45 mmol/
mol (6.3%) (95% CI 6.17, 6.51) in relation to FPG.
Segmented regression analysis of OGTT 2-h level on
HbA1c values showed a breakpoint on HbA1c value at
42 mmol/mol (6.0%) (95% CI 5.84, 6.18) in relation to
OGTT 2-h value. These statistically derived breakpoints
reveal a strong association between HbA1c values and
OGTT fasting plasma glucose values and OGTT 2 h-values at HbA1cvalues 6.3% and 6.0% respectively,. This
emphasises the integrity of the data.
ROC analysis showed an association between OGTT
(gold standard) and HbA1c values (test variable) as diag-
nostic parameters for DM with AUC 0.73 (95% CI 0.63,
0.84). AUC was independent of the difference in timing
of blood sampling between OGTT results and HbA1c
values. There was no statistically significant association
between OGTT results and HbA1c values in the inter-
mediate hyperglycaemia category (AUC 0.56) (Table 2).
Table 3 shows the number of patients categorized as
having normoglycaemia, intermediate hyperglycaemia
and DM according to HbA1c values versus OGTT re-
sults, and the distribution of patients within the different
glycaemic categories. According to OGTT results, 33
patients had DM, 90 patients had intermediate hypergly-
caemia and 152 patients had normoglycaemia. Forty pa-
tients had DM according to HbA1c values. Fifteen
patients were diagnosed with DM by both criteria, giving
a sensitivity of 45.5%. The number of patients without
DM by either criterion was 217 (Figure 2a). Ninety pa-
tients had intermediate hyperglycaemia according to
OGTT results, and based on HbA1c values these were
classified similarly in 63% of the cases whereas 22% were
grouped as having DM (Table 3, Figure 2b). According
to HbA1c criteria 193 patients had intermediate hyper-
glycaemia. The number of patients without intermediate
hyperglycaemia by either criterion was 49 (Figure 2b).
HbA1c values combined with FPG classified 46 pa-
tients as having DM, and diagnosed DM with a sensitiv-
ity of 64% and specificity of 90%.
Discussion
The purpose of this study was to validate HbA1c as a
method to diagnose DM in vascular surgery patients by
comparing HbA1c values with the OGTT results. In this
study the prevalence of DM and intermediate hypergly-
caemia was higher based diagnosis through measuring
the HbA1c values compared with OGTT results (Table 3).
The two parameters defined the same individuals as
having diabetes in only 45.5% of the cases (Table 3,
Figure 2a). HbA1c combined with FPG had a higher sen-
sitivity (64%) compared to HbA1c alone. There was a sig-
nificant correlation between OGTT and reduced renal
function (p = 0.04). No such correlation was seen for
HbA1c.
This was a prospective study with a well-defined study
population of patients with advanced macrovascular dis-
ease. The selection of the study population was not
based on FPG values. As a result, patients with normal
FPG and elevated OGTT 2-h value were also diagnosed
correctly. HbA1c was measured in a standardised way to
ensure the accuracy of the values measured. Medical
conditions with abnormal red cell turnover may affect
Table 2 Area under curve and summary statistics of HbA1c cut-off of 6.5 nmol/l for all patients, for patients with GFR
≥60 and for patients with GFR <60
Parameters All patients Where GFR≥ 60 Where GFR < 60
No. 275 201 74
Area under curve (95% CI) 0.73 (0.63, 0.84) 0.71 (0.57, 0.84) 0.78 (0.63, 0.94)
Sensitivity (95% CI) 0.45 (0.28, 0.64) 0.46 (0.26, 0.67) 0.44 (0.14, 0.79)
Specificity (95% CI) 0.90 (0.85, 0.93) 0.92 (0.87, 0.96) 0.83 (0.72, 0.91)
Positive predictive value (95% CI) 0.38 (0.23, 0.54) 0.44 (0.24, 0.65) 0.27 (0.08, 0.55)
Negative predictive value (95% CI) 0.92 (0.88, 0.95) 0.93 (0.88, 0.96) 0.92 (0.81, 0.97)
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Haemoglobinopathies in Norway are mainly present in
persons with African or Asian ethnic origin [23]. The
study population was of European descent and there
were no significant differences in the prevalence of an-
aemia, suggesting that anaemia and abnormal haemoglo-
bin did not affect the validity of the results. The fact that
121 patients out of 467 declined to participate in the
study might introduce a selection bias. However, the
mean FPG values and the prevalence of DM based on
FPG levels alone were the same in the 121 patients as in
the study group.
Newly diagnosed DM
In contrast to most other studies an HbA1c value
≥48 mmol/mol (6.5%) was associated with a higher
prevalence of DM in this study when compared with
OGTT results (14.6% vs. 12.0%) (Table 3). The sensitiv-
ity of HbA1c compared with the OGTT in this study was
45.5%. Doerr et al performed coronary angiography in
patients with coronary heart disease and found a lower
prevalence of newly detected diabetes when using the
HbA1c criteria compared with the OGTT (4% vs. 14%)
[20]. Results from major epidemiological studies on gen-
eral populations also demonstrated a lower prevalence
of diabetes by HbA1c criteria compared with OGTT
[14-16]. This corresponds with results from studies on
populations at risk of developing DM [17,21]. A recentTable 3 The number of patients categorized as having normo
according to HbA1c
a versus OGTTb results, and the distributi
OGTTb Subjects Nor
glycaem
Total 275 42 (
Normoglycaemia 152 27 (
Intermediate hyperglycaemia 90 13 (
Diabetes mellitus 33 2 (
a HbA1c ≥ 6.5% (48 mmol/mol) = diabetes mellitus, HbA1c range of 5.7-6.4% (39-46 m
HbA1c < 5.7% (39 mmol/mol) = normoglycaemia.
b FPG + 2-h value. DM = FPG ≥ 7.0 mmol/l and/or two-h value ≥ 11.1 mmol/l. Interm
between 7.8 mmol/L and 11.1 mmol/L, and IFG defined as fasting glucose value be
FPG < 6.1 mmol/L and a 2-h-value < 7.8 mmol/L.metaanalysis demonstrated that performing an OGTT
during acute coronary syndrome did not impede the
diagnostic accuracy of the test. The study did not com-
pare HbA1c with the OGTT [24].
Similar to the results presented in this paper, Mostafa et
al found an increased prevalence of DM using HbA1c cri-
teria compared with the OGTT in a population based
study on a multi-ethnic cohort[25]. Several explanations
for the increased prevalence of DM by HbA1c criteria
in the population of vascular surgery patients may be
presented. HbA1c value measurements are influenced by
high age, male sex, kidney failure and ethnicity [8,22,26],
and pretest probability is influenced by the risk of DM de-
velopment. All factors were present in this study, except
that the study population consisted of white Europeans.
On the contrary, Martins et al found that in older adults,
females presented higher values of HbA1c than men, and
that HbA1c is not affected by age[27]. Participants with
IGT and/or DM were excluded.
Intermediate hyperglycaemia
An intermediate HbA1c value range has been suggested
to identify individuals in need for preventive interven-
tions [8,9]. An interesting observation in this study is
the high number of patients with intermediate hypergly-
caemia as defined by HbA1c in contrast to OGTT (70%
vs. 33%) (Figure 2b). The prevalence of intermediate
hyperglycaemia in the National Health and Nutritionglycaemia, intermediate hyperglycaemia and DM
on of patients within the different glycaemic categories
HbA1c
a
mo-
ia (%)
Intermediate
hyperglycaemia (%)
Diabetes
mellitus (%)
15.3) 193 (70.2) 40 (14.6)
17.8) 120 (79.0) 5 (3.3)
14.4) 57 (63.3) 20 (22.2)
6.1) 16 (48.5) 15 (45.5)
mol/mol) = intermediate hyperglycaemia, and
ediate hyperglycaemia = IGT defined as FPG < 7.0 mmol/L and a 2-h-value
tween 6.1 mmol/L and 7.0 mmol/L with a normal 2-h-value. Normoglycaemia =
Figure 2 Venn diagrams. a The prevalence of newly diagnosed DM by OGTT results (FPG≥ 7.0 mmol/l and/or 2-hour value≥ 11.1 mmol/l) (red
circle) and by HbA1c value≥ 6.5% (48 mmol/mol) (blue circle). The prevalence of diabetes mellitus was higher when using HbA1c criteria, and
HbA1c classified 46% of the 33 patients with newly diagnosed diabetes mellitus in concordance with OGTT results. b The prevalence of
intermediate hyperglycaemia by OGTT results (FPG 6.1 mmol/l – 7.0 mmol/l and/or 2-hour value 7.8 mmol/l – 11.1 mmol/l) (red circle) and by
HbA1c value 5.7% - 6.4% (39-46 mmol/mol) (blue circle). The prevalence of intermediate hyperglycaemia was higher when using HbA1c criteria
compared with OGTT results.
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that of OGTT results [15]. In contrast, among coronary
heart disease patients the prevalence of intermediate
hyperglycaemia using HbA1c criteria was similar to that
of OGTT results [20]. Major prospective studies indicate
an increased risk of developing DM in patients within the
intermediate hyperglycaemia range of HbA1c [28-31].Clinical interpretations
Existing literature is often challenging to interpret as pre-
vious studies were performed on various mixtures of study
populations; populations with diabetes, populations with-
out diabetes and mixed populations. This study was
performed on patients with advanced macrovascular dis-
ease and a mixture of glucometabolic states. HbA1c has
been considered as a risk predictor for subsequent dia-
betes and microvascular disease [2-5,28], and has been
proposed as a risk predictor for macrovascular disease in
people with DM [6,29]. However, studies on patients with
established coronary heart disease have shown that the
OGTT and not HbA1c is the best predictor for the
macrovascular disease [20,32,33]. Both this and previously
performed studies [14-17,20,21] have shown that the
OGTT and HbA1c define different categories of patients
as having DM and intermediate hyperglycaemia. HbA1c
describes long-term glycaemic burden and represents a
different metabolic expression to OGTT. The high preva-
lence of DM and intermediate hyperglycaemia when using
HbA1c in this study may reflect a high chronic glycaemic
burden in patients with peripheral arterial disease.
The clinical importance of the high number of patients
with DM and intermediate hyperglycaemia in this study
with advanced macrovascular disease, whether defined
by HbA1c or OGTT, is unknown. Future studies are
needed to identify which test, the OGTT or the HbA1c,
is the better in predicting the clinical outcome invascular surgery patients and in defining the patients in
need for treatment or preventive intervention.
Limitations
The sample size of this study with participants from a spe-
cific high-risk population was relatively small. The discord-
ance between OGTT results and HbA1c values reveald the
challenge when using a gold standard, i.e. that any other
test will be inferior. Ideally, it would be preferable to use an
external diagnostic and prognostic parameter, for example
the prevalence of retinopathy, in order to compare HbA1c
with the OGTT. Due to logistic reasons, some OGTTs
were not performed at standard conditions in the hospital
for all patients. This reflects the clinical reality where the
diagnosis of DM is mostly done by the primary health care
provider. For the same reasons, the HbA1c values were not
measured at the same time as the OGTT for all patients.
Separate analyses were performed on those patients who
had their HbA1c values measured between one month and
two months after the time that their OGTT was performed.
There were no significant differences in the results. It
would have been preferable to use the mean of two fasting
glucose levels, two two-hour glucose levels and two HbA1c
values for statistical analysis to secure reproducibility of the
results. The International Expert Committee, American
Diabetes Association and the WHO have suggested re-
peated HbA1c measurements as a diagnostic criterion for
type 2 DM [8-10]. However, large epidemiological studies
have used the results from one single measurement of
FPG, two-hour value and HbA1c, thus making the results
from this study comparable to other studies. Finally, it
would have been preferable to have used body mass index
as an adjustment variable, but this was not registered.
Conclusion
In vascular surgery patients an HbA1c value of ≥48 mmol/
mol (6.5%) had a 45.5% sensitivity, and a 90% specificity
Hjellestad et al. Cardiovascular Diabetology 2013, 12:79 Page 8 of 9
http://www.cardiab.com/content/12/1/79when compared to the OGTT when diagnosing DM. The
total prevalence of pathologic glucose metabolism was sub-
stantially higher based on HbA1c values than based on
OGTTs. The two parameters, the OGTT and the HbA1c,
categorized different individuals with DM and intermediate
hyperglycaemia. The high prevalence of DM and intermedi-
ate hyperglycaemia when using HbA1c values in this study
may reflect a high chronic glycaemic burden in patients
with peripheral arterial disease. Further studies on vascular
surgery patients are needed to identify which method, the
OGTT or the HbA1c, is the better in predicting DM and fu-
ture clinical development of vascular disease.
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